Ezutromid

• Catalog number
  B1248-25
• Price
  Please ask
• Size
  25 mg

• Alternative_name
  5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole; BMN195
• Description
  Ezutromid is a first orally available drug for the treatment of Duchenne muscular dystrophy (DMD), a lethal, X-linked muscle wasting disease caused due to lack of dystrophin-a cytoskeleton protein. Ezutromid has shown potential as disease modifying treatment for DMD patients irrespective of their gene mutation. Ezutromid acts on utrophin modulation and has potential to slow down or stop the progression of DMD.
• CAS Number
  945531-77-1
• Structure Available
  Yes
• Salt Form
  No
• Molecular Formula
  C₁₉H₁₅NO₃S
• Molecular Weight
  337.39
• Cell Permeable
  Yes
• Purity
  ≥98% by HPLC
• Solubilities
  DMSO(>10 mg/ml)
• Handling
  Protect from air and light
• Tag Line
  A drug for the treatment of Duchenne muscular dystrophy (DMD),
• Storage Condition
  -20°C
• Shipping Condition
  gel pack
• Shelf Life
  36 months
• PubChem CID
  25109292
• PubChem CID Link
• SMILES
  CCS(=O)(=O)C1=CC2=C(C=C1)OC(=N2)C3=CC4=CC=CC=C4C=C3
• InChi
  InChI=1S/C19H15NO3S/c1-2-24(21,22)16-9-10-18-17(12-16)20-19(23-18)15-8-7-13-5-3-4-6-14(13)11-15/h3-12H,2H2,1H3
• InChi Key
  KSGCNXAZROJSNW-UHFFFAOYSA-N
• Data Sheet Link
• MSDS Available
  Yes

• Gene target
  Ezutromid  
• Short name
  Ezutromid
• Alternative name
  Ezutromid

Similar products